Prevail Therapeutics Inc is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. They are applying a precision medicine approach to neurodegeneration by studying gene therapies in genetically defined patient populations. They believe this will increase the probability of creating disease-modifying therapies that improve patients’ lives. Their lead program is PR001 for the treatment of Parkinson’s disease with GBA1 mutation, or PD-GBA, and neuronopathic Gaucher disease. They are focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc incorporated under the laws of the State of Delaware in July 2017. Their
principal executive offices are located at 430 East 29th Street, Suite 940, New
York, New York 10016.